Tuesday, December 7, 2021
7:00 p.m. to 8:00 p.m. ET
Virtual

This evidence-based program will provide pharmacists with updates on best practices for identifying influenza and guiding the use of antiviral therapy, which is currently underused, even among high-risk patients who are susceptible to worse outcomes.
The program will acquaint pharmacists with shifts in influenza diagnosis and care that have been prompted by the emergence of COVID-19, and the availability of a first-in-class oral antiviral agent, for which data, indications, and formulations continue to accumulate, warranting immediate practice changes in both treatment and prophylaxis.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Identify appropriate candidates for antiviral therapy based on risk for influenza-related complications, in accordance with
  current guideline recommendations
• Differentially diagnose influenza based on clinical presentation and accurate interpretation of appropriate diagnostic tests
  when necessary
• Recommend individualized antiviral treatment plans for patients with influenza based on current data and unique agent
  characteristics
• Advise on influenza prophylaxis based on evidence and in accordance with guideline recommendation

Speaker

Jason Bowling, MD, FIDSA
Associate Professor
Department of Medicine
Division of Infectious Diseases
UT Health San Antonio

Registration

There is no cost to attend, but registration is required.

REGISTRATION IS NOW CLOSED.

Note: Zoom link will be emailed to all registered attendees on the day of the Webinar.